These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 22430630)

  • 21. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy.
    Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
    Prostate; 2012 Feb; 72(3):270-9. PubMed ID: 21630293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L; Egevad L; Ekman P; Hellström M
    Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B; Alkibay T; Tuncel A; Bozkirli I
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
    Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H
    Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
    Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
    Lein M; Semjonow A; Graefen M; Kwiatkowski M; Abramjuk C; Stephan C; Haese A; Chun F; Schnorr D; Loening SA; Jung K
    J Urol; 2005 Dec; 174(6):2150-3. PubMed ID: 16280753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
    Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
    Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
    Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
    Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
    BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of NIH-IV prostatitis on free and free-to-total PSA.
    Stancik I; Lüftenegger W; Klimpfinger M; Müller MM; Hoeltl W
    Eur Urol; 2004 Dec; 46(6):760-4. PubMed ID: 15548444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
    Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
    J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer?
    Ohori M; Dunn JK; Scardino PT
    Urology; 1995 Nov; 46(5):666-71. PubMed ID: 7495118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
    Egawa S; Suyama K; Matsumoto K; Kuwao S; Baba S
    J Urol; 2002 Jan; 167(1):97-102. PubMed ID: 11743284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.